Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat). Local targets link to admitted publications; unresolved targets remain external evidence.
Global burden of thrombosis: epidemiologic aspects
10.1161/circresaha.115.306841 · 2016 · External reference
Global health burden of venous thromboembolism
10.1161/atvbaha.124.320151 · 2024 · External reference
Triggers, targets and treatments for thrombosis
10.1038/nature06797 · 2008 · External reference
Thrombosis: a major contributor to the global disease burden
10.1111/jth.12698 · 2014 · External reference
Unresolved reference
2024 · External reference
Cardioembolic stroke: an update
10.1016/s1474-4422(03)00324-7 · 2003 · External reference
Prevention of venous thromboembolism in 2020 and beyond
10.3390/jcm9082467 · 2020 · External reference
Oral anticoagulants beyond warfarin
10.1146/annurev-pharmtox-032823-122811 · 2024 · External reference
Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review
10.1007/s12325-022-02333-9 · 2023 · External reference
DOACs vs vitamin K antagonists: a comparison of phase III clinical trials and a prescriber support tool
10.3889/oamjms.2019.289 · 2019 · External reference
Assessing bleeding risk in patients taking anticoagulants
10.1007/s11239-013-0899-7 · 2013 · External reference
Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study
10.1161/jaha.119.014108 · 2020 · External reference
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: proceedings, Washington, DC, December 3-4, 2012
10.1016/j.ahj.2014.04.007 · 2014 · External reference
New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors
10.1161/atvbaha.123.318781 · 2023 · External reference
Factor XI as a therapeutic target
10.1161/atvbaha.116.306925 · 2016 · External reference
Intrinsic pathway of coagulation and arterial thrombosis
10.1161/atvbaha.107.155952 · 2007 · External reference
The intrinsic pathway of coagulation: a target for treating thromboembolic disease?
10.1111/j.1538-7836.2007.02446.x · 2007 · External reference
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo
10.1182/blood-2010-02-270918 · 2010 · External reference
Structure and function of factor XI
10.1182/blood-2009-09-199182 · 2010 · External reference
Phenotypic and genetic analyses of four cases of coagulation factor XII deficiency
10.1080/16078454.2022.2083482 · 2022 · External reference
Hereditary factor XII deficiency in an adult patient: a case report
10.1177/2050313x221118728 · 2022 · External reference
Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients
10.1093/omcr/omaa146 · 2021 · External reference
Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
10.1038/s41467-025-62789-5 · 2025 · External reference
Reduced incidence of ischemic stroke in patients with severe factor XI deficiency
10.1182/blood-2007-10-120139 · 2008 · External reference
Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis
10.1160/th10-05-0307 · 2011 · External reference
Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events
10.1182/blood-2016-09-742262 · 2017 · External reference
Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy
10.1111/j.1365-2516.2006.01304.x · 2006 · External reference
Factor XI deficiency in Ashkenazi Jews in Israel
10.1056/nejm199107183250303 · 1991 · External reference
Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment
10.1182/blood.2023020721 · 2024 · External reference
Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis
10.1016/j.rpth.2025.102860 · 2025 · External reference
Factor XI antisense oligonucleotide for prevention of venous thrombosis
10.1056/nejmoa1405760 · 2015 · External reference
Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial
10.1001/jama.2019.20687 · 2020 · External reference
Milvexian for the prevention of venous thromboembolism
10.1056/nejmoa2113194 · 2021 · External reference
Abelacimab for prevention of venous thromboembolism
10.1056/nejmoa2105872 · 2021 · External reference
Abelacimab versus rivaroxaban in patients with atrial fibrillation
10.1056/nejmoa2406674 · 2025 · External reference
Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—systematic review and meta-analysis
10.1111/jth.15890 · 2022 · External reference
Asundexian for secondary stroke prevention
10.1056/nejmoa2513880 · 2026 · External reference
Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials
10.1016/s0140-6736(25)02097-5 · 2025 · External reference
Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation
10.1161/jaha.115.002322 · 2015 · External reference
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
10.1073/pnas.1323896111 · 2014 · External reference
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
10.1073/pnas.1324022111 · 2014 · External reference
Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
10.1111/jth.14418 · 2019 · External reference
An update on factor XI structure and function
10.1016/j.thromres.2017.10.008 · 2018 · External reference
A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain
10.1182/blood-2015-10-676122 · 2016 · External reference
MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans
10.1182/blood-2018-10-880849 · 2019 · External reference
Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI
10.1016/j.jmb.2019.09.008 · 2019 · External reference
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
10.1111/cts.13148 · 2022 · External reference
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
10.1111/jth.15700 · 2022 · External reference
Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay
10.1309/ajcpq2njd3pxftug · 2015 · External reference
Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI
10.1161/strokeaha.119.026545 · 2019 · External reference
Dabigatran versus warfarin in patients with mechanical heart valves
10.1056/nejmoa1300615 · 2013 · External reference
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
10.1016/s0140-6736(13)62343-0 · 2014 · External reference
Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels
2017 · External reference
Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease
10.1016/j.ajhg.2012.05.009 · 2012 · External reference
Genetically determined FXI (factor XI) levels and risk of stroke
10.1161/strokeaha.118.022792 · 2018 · External reference
